Micreos' Alternative to Antibiotics Secures Next €25 Million

Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of €25 million in growth capital and for clinical development of its endolysin technology platform, set to replace

Related Keywords

Germany ,Wageningen ,Gelderland ,Netherlands ,United States ,United Kingdom ,Bilthoven ,Utrecht ,France ,Switzerland ,Dutch ,Swiss ,Mark Offerhaus ,Micreos Pharma ,Kostenloser Wertpapierhandel ,Matt Regan ,Micreos Pharmaceuticals ,Technology Center ,Swiss Federal Technology Institute ,Development Team In Bilthoven ,Over The Counter Consumer Health ,Bloodstream Infections ,Atopic Dermatitis ,Diabetic Foot Ulcers ,Cutaneoust Cell Lymphoma ,Counter Consumer Health ,Development Team ,Micreos Food Safety ,Corporate Communication Micreos ,Micreos ,Alternative ,Antibiotics ,Ecures ,Text ,Billion ,